Home Research Reports Technological Innovations to turn the tide in favour of Revenue Generation in treatment of ailments related to sensory organs
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Technological Innovations to turn the tide in favour of Revenue Generation in treatment of ailments related to sensory organs

by Jackson B
Technological Innovations to turn the tide in favour of Revenue Generation in treatment of ailments related to sensory organs

Australia and New Zealand surgical and respiratory masks market is being driven by the growing infections therein. The WHO has stated that Covid-19 has affected more than 5000 people all over Australia and New Zealand till March 2020. On the developments’ front, 3M, around the entered into partnership with Ford Motor Company for increasing production of PAPRs for helping in meeting the increase in demand for PPE kits to cope with Corona. It is still “on”.

Hemodynamic monitoring implies catering to chronic diseases like diabetes and cardiac disorders, along with growing demand for non-invasive and home-based monitoring systems. The private players are also coming forward to devise various measures for helping out people suffering from hypertension.

Dermatophytic onychomycosis treatment, by type of product, spans nail paints and tablets. By route of administration, it’s topical and oral. Type-wise, it’s over-the-counter and prescribed. Research states that 33% of the overall fungal infections are onychomycosis. Coming to developments, Kaken Pharmaceuticals Co., Ltd., in March 2020, did announce launching Jublia in Hong Kong. Moberg Pharma AB, in February 2019, did ink a license agreement with “Bayer AG” for marketing, selling, and distributing MOB-015 all across the Europe.

North America toxicology laboratories are expected to witness a double-digit CAGR in the next 10 years. This could be attributed to increasing intervention of the government authorities regarding abuse of the controlled substances and subsequent regulations with regards to deterring the illicit drugs’ controlled consumption, and feasible reimbursement policies regarding conduction of toxicity testing. By drug class, the market spans alcohol, benzodiazepines, barbiturates, amphetamines, opioids/opiates, tricyclic anti-depressants, and Z drugs.

Sleep service providers, based on end-user, could be sleep centers, hospitals, and home care settings. As per a review of epidemiological studies presented in June 2019, (at the yearly meeting of the Associated Professional Sleep Societies in San Antonio), the obstructive sleep apnea is likely to affect close to 37% of those above 18 in the Americas. Also, reimbursement scenario in Canada is quite in favour of the consumers of sleep services.

Holter monitoring systems, by product, consist of Holter monitoring software, Holter monitoring devices, and event monitoring devices. The basic advantage of event monitoring devices is that they could be used for more than a month. As such, even an unbalanced heartbeat could be regularized for marking permanent record. Holter monitoring devices could be worn for 24-48 hours.

Transcatheter heart valve replacement, by product, spans transcatheter aortic valve replacement, transcatheter pulmonary valve replacement, and transcatheter mitral valve repair and replacement. Coming to surgical approach, it’s transapical approach and transfemoral approach. Application-wise, it’s aortic valve stenosis, aortic valve recognition, mitral valve stenosis, mitral valve regurgitation, and pulmonary valvular heart disease.

Asia-Pacific Alopecia treatment has been doing the rounds with frequent disturbances in hair growth cycle. In case of women, the reasons could be pregnancy, stress, anemia, and in case of both – male and female, they could be deficiency of vitamin B, hypothyroidism, autoimmune disorders, over-exposure to sunlight, pattern baldness, chemotherapy, and likewise. Alcoholism could also be one of the reasons of alopecia. Aesthetic drugs are being tried out, in addition to conventional therapies like hair mask, oil massage.

As far as neuropathic pain is concerned, the drug class includes tricyclic anti-depressants, anticonvulsants, SNRI’s, capsaicin cream, local anaesthesia, opioids, steroids, and others. Diagnosis-wise, it’s post-herpetic neuralgia, trigeminal neuralgia, diabetic neuropathy, chemotherapy-induced peripheral neuropathy, and others. Coming to developments, Merck & Co., in the year 2019, did collaborate with FMedSci for developing a new series of pain treatment.

Hepatitis C Drug, product-wise, span NS5A Inhibitors like Protease Inhibitors, fixed-dose combination, and others. By type of disease, it’s acute Hepatitis C and chronic Hepatitis C. Distribution-channel-wise, it’s retail, hospital, and online. Mavyret from AbbVie is ruling the roost as of now, due to shorter course of treatment and cost-effectiveness.

Persistence Market Research (PMR) has profiled the key participants in various ailments and courses of treatment listed above as follows:

  • Vertex Pharmaceuticals Inc.
  • Gilead Sciences, Inc.
  • Sanofi S.A.
  • GlaxoSmithKline
  • Medtronic’
  • Abbott
  • Histogen Inc.
  • Cipla
  • HCell Inc.
  • Midmark Corp.
  • BPL Medical Technologies
  • SOVA Sleep Services Inc.
  • Midwest Sleep Services Inc.
  • Alere Inc.
  • Agilent Technologies
  • Kaken Pharmaceuticals Co. Ltd.
  • Galderma
  • GE Healthcare
  • Getinge AB
  • Halyard Healthcare Inc.
  • Medline Industries

You may also like